← Back to Search

CAR T-cell Therapy

CD30.CAR-EBVST cells for Nasal Lymphoma

Phase 1

Waitlist Available

Led By Premal Lulla, MD

Research Sponsored by Baylor College of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new treatment for lymphoma that involves taking T cells from a healthy donor and training them to recognize and kill cancer cells.

Eligible Conditions

Nasal Lymphoma
Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicity rate (DLT) by CTCAE 5.0

Secondary outcome measures

Duration of Response

Duration of SD

Progression free survival (PFS)

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment PhaseExperimental Treatment1 Intervention

Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered. The total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially. Dose Level 1: 1 × 10^8 CD30.CAR-EBVST cells Dose Level 2: 4 × 10^8 CD30.CAR-EBVST cells Dose Level 3: 1 × 10^9 CD30.CAR-EBVST cells

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The Methodist Hospital Research InstituteOTHER

271 Previous Clinical Trials

80,375 Total Patients Enrolled

Baylor College of MedicineLead Sponsor

1,001 Previous Clinical Trials

6,001,952 Total Patients Enrolled

Premal Lulla, MDPrincipal InvestigatorBaylor College of Medicine

4 Previous Clinical Trials

171 Total Patients Enrolled

Media Library

CD30.CAR-EBVST cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04952584 — Phase 1

Nasal Lymphoma Research Study Groups: Treatment Phase

Nasal Lymphoma Clinical Trial 2023: CD30.CAR-EBVST cells Highlights & Side Effects. Trial Name: NCT04952584 — Phase 1

CD30.CAR-EBVST cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04952584 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any slots open at the moment for this research endeavor?

"The information posted on clinicaltrials.gov indicates that this trial, which was initially published in January 1st 2023 and amended most recently on August 1st 2022, is not presently recruiting participants. Notwithstanding the lack of enrollment for this particular study, 1752 other trials are open to patients at present."

Answered by AI

Does the protocol for this trial permit those aged 65 or above to participate?

"For recruitment purposes, this trial is looking for individuals aged between 12 and 75."

Answered by AI

Is it possible for me to participate in this medical experiment?

"This medical trial is in search of 18 individuals, aged between 12 and 75, with ALK-negative anaplastic T cell lymphoma or other peripheral T-cell lymphomas."

Answered by AI

How perilous is the use of CD30.CAR-EBVST cells for humans?

"Our team at Power evaluated the safety of CD30.CAR-EBVST cells and rated it a 1 due to its status as an early phase clinical trial, meaning there is minimal data supporting both efficacy and safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Premal Lulla 2024. "Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04952584.